BMJ Open Acceptance Rate

That table gives the honest answer. BMJ Open is not a fallback where anything methodologically decent goes through. A 27% acceptance rate means the journal is filtering harder than many broad-scope OA medical journals, even though it is not screening for the same prestige signals as BMJ, JAMA, or NEJM.

Trend guardrail: BMJ Open's public journal statistics page gives a current 27% figure, not a public year-by-year acceptance-rate series by article type. Do not claim the rate is up from 20% or down from 40% unless you have a dated BMJ source for the older denominator; use 27% as the current official planning snapshot.

The BMJ Open journal page is the best cluster reference if you want to compare this acceptance-rate signal against fit, review time, and APC context. This page stays focused on the 27% selectivity signal and what it means for manuscript fit.

Evidence basis: this page was updated from BMJ Open's public journal statistics, BMJ Open author guidance, the editorial-board page, a small recent-article sample, Manusights query-routing checks, and Manusights submission-readiness review patterns. Manusights submission analysis identifies the repeated acceptance-rate trap: authors treat 27% as odds before checking whether the Methods, ethics, reporting checklist, and conclusions can survive open peer review. This page helps authors decide whether the 27% selectivity signal is about journal fit, desk-screen risk, and submission readiness.

Before you use the percentage to choose a target, a BMJ Open submission-readiness check can test the methods, reporting, ethics, and claim discipline that change whether the 27% figure is realistic for your manuscript.

BMJ Open's 27% acceptance rate is an all-journal figure. It does not say whether a protocol, systematic review, qualitative study, diagnostic paper, trial report, or cross-sectional survey faces the same path. Article type changes both the editorial screen and the reviewer job.

Protocols are judged on whether the question, design, registration, outcomes, ethics approval, and analysis plan are already coherent. Systematic reviews need a defensible search strategy, screening process, protocol trail, and PRISMA implementation. Observational studies need exposure definitions, confounding control, sample-size logic, and conclusions that avoid causal overreach. Qualitative studies need sampling rationale, reflexivity, coding transparency, and enough context for readers outside the specialty.

Desk review also changes the apparent odds. A manuscript can fail quickly because it is outside article type, missing ethics or consent documentation, using a checklist as decoration rather than evidence, or making claims the study design cannot carry. Papers that reach full review face a different test: whether the Methods, Results, tables, figures, limitations, and data-sharing statement remain consistent under public reviewer scrutiny.

The acceptance rate tells you BMJ Open is selective enough that authors should stop treating it like a low-bar megajournal. It does not mean the journal is secretly prestige-driven.

What it tells you:

• the editorial screen is real

• broad-scope does not mean permissive on weak methods

• the journal has room to reject incomplete or poorly framed work early

What it does not tell you:

• how many of the rejections are desk decisions versus full-review rejections

• how protocols, observational studies, systematic reviews, and qualitative work behave relative to each other

• whether the main problem is methodology, ethics documentation, or simple scope mismatch

• whether your budget can absorb the current £2,390 GBP APC if an institutional agreement, waiver, or discount does not apply

That is why the number helps with orientation, but not with final targeting.

Do not average acceptance rate and citation context into a single "worth it" score. They answer different questions.

The 27% acceptance rate is a selectivity signal: BMJ Open is accessible compared with elite general-medicine journals, but it still rejects most submissions. Citation-metric questions belong on the dedicated metrics page, not on this acceptance-rate page.

For authors, the practical decision is this:

In our BMJ Open reviews, the strongest decisions start with manuscript shape, not metric order. A protocol with complete registration, outcomes, ethics approval, and analysis logic may fit BMJ Open better than a flashier finished paper with unsupported clinical claims. Conversely, a high-consequence clinical study may deserve a JAMA Network Open or The BMJ attempt even if BMJ Open looks safer on acceptance rate.

The 27% figure is an all-journal selectivity signal, not a paper-level prediction. It does not say whether a protocol, cross-sectional study, qualitative paper, systematic review, or trial report has the same odds. It also does not tell you whether the first decision will be fast enough for a thesis, grant, or promotion deadline.

It also should not be blended with separate citation-context measures such as CiteScore or SJR. Those can describe literature reach, but they are not acceptance-rate predictors.

This page uses recent article checks only to ground the venue shape, not to infer a private acceptance formula. The June 2026 sample included a domiciliary-care study protocol (doi:10.1136/bmjopen-2026-117555), a systematic-review protocol on spin in medical decision-making (doi:10.1136/bmjopen-2026-117998), and a community climate-and-health cross-sectional study (doi:10.1136/bmjopen-2026-117256). That mix supports the practical reading: BMJ Open has room for solid applied medical work, but the package has to make study design, reporting, and limitations easy to verify.

The official pages and the review culture point to a consistent first-pass screen:

1. Is the study design appropriate to the question?

1. Is reporting complete enough for open peer review?

1. Are ethics, consent, registration, and data-availability statements in order?

1. Does the paper matter to a broad medical or public-health readership, even if it is not a prestige-journal story?

Open peer review matters here. BMJ Open publishes reviewer reports and earlier manuscript versions with accepted papers. That means weak reporting or slippery framing is harder to hide than in a conventional closed-review model.

In our pre-submission review work with BMJ Open authors, the acceptance-rate question usually fails when authors ask "what are my odds?" before checking the manuscript components that editors can verify. We treat this as a specific failure pattern: the journal's broad scope helps only after the abstract, Methods, Results, tables, figures, ethics statement, reporting checklist, sample-size rationale, limitations, and data-availability language all support the same bounded claim.

Checklist compliance is claimed but not actually implemented. We see STROBE, CONSORT, PRISMA, or COREQ checklists attached to the submission package, but the manuscript itself still lacks key required details. BMJ Open is more likely than many authors expect to treat that gap as a real editorial problem rather than a formality issue.

Observational studies overclaim. A technically competent cohort, cross-sectional, or registry study often gets into trouble when the Results and Discussion drift into causal language that the design cannot support.

Ethics and transparency sections are underbuilt. Missing committee names, absent approval numbers, vague consent language, or weak data-sharing statements are repeated early failure modes.

The acceptance-rate implication is different for each pattern. A BMJ Open observational paper with a clear exposure definition, justified covariates, conservative conclusion language, and complete STROBE trail is not competing on the same surface as a paper that only has a large dataset. A BMJ Open protocol with registration, outcome definitions, ethics approval, recruitment logic, and a plausible analysis plan can be a cleaner fit than a finished paper whose Methods are vague.

In our reviews, the strongest BMJ Open candidates make the editor's first pass boring in the right way: the manuscript tells the same story in the abstract, tables, figures, Methods, limitations, and data statement, so the 27% figure becomes a realistic hurdle rather than a warning that the package is underbuilt.

That is why the acceptance-rate question is only half the story. For BMJ Open, the live issue is often not whether the paper is exciting enough. It is whether the manuscript is clean enough.

For BMJ Open, the better decision question is:

Is this manuscript methodologically sound, transparently reported, and framed with conclusions the design can actually support?

If yes, the 27% acceptance rate is a serious but realistic hurdle. If no, the rate is not the bottleneck. The manuscript package is.

The live official answer is straightforward: BMJ Open currently reports a 27% acceptance rate.

The better operating answer is:

• BMJ Open is selective enough that sloppy submissions get filtered

• the journal still evaluates more on soundness than on prestige signaling

• authors should treat reporting completeness and design discipline as the real decision surface

If you want to pressure-test whether the manuscript actually behaves like a BMJ Open paper before submission, a BMJ Open submission readiness check is the best next step.